Pengyang Medical Completes Series B+ Financing to Accelerate Industrialization of Cardiovascular Full-Cycle Products and Ecosystem Development

VCBeat (WeChat ID: vcbeat) has learned thatBeijing Pengyang Fengye Medical Equipment Co., Ltd. (abbreviated as: Pengyang Medical) – The Global Exclusive Provider of Patented 18-Lead Dynamic ECG Products and Cardiovascular Diagnostic Service Platforms, recently completed a Series B+ financing round amounting to tens of millions of RMB, jointly invested by Suzhou Wuzhong Economic Development Technological Innovation Investment Partnership (Limited Partnership) and Suzhou Wuzhong Economic Development Intelligent Manufacturing Investment Partnership (Limited Partnership). Through this round of financing, Pengyang Medical will accelerate the R&D, regulatory registration, and industrial commercialization of its full-cycle cardiovascular products, laying a solid foundation and providing strong assurance for building China’s most authoritative cardiovascular diagnostic service platform, establishing an ecosystem for comprehensive lifecycle management of cardiovascular diseases, and pursuing an initial public offering (IPO).

Previously, the company secured Series A and Series B financing from CCB Medical Growth Fund and Jiuwei Fund.

Pengyang Medical specializes in technological innovation, as well as the research and development, manufacturing, and sales of products in the cardiovascular field. The company has developed a series of intelligent monitoring and AI-driven diagnostic products, represented by its globally exclusive patented product—the 18-lead ambulatory ECG analysis system. Eight of its products have obtained NMPA approval, three have received CE certification, and 36 new products are currently under development or regulatory review. As a high-end manufacturer with leading original research capabilities and strong product commercialization expertise, Pengyang Medical is recognized as a National High-Tech Enterprise and a Beijing “Specialized, Refined, Differential, and Innovative” (SRDI) Enterprise.

Pengyang Medical is the only enterprise awarded the title of “18-Lead Ambulatory ECG Technology R&D Base” by the Chinese Society of Electrocardiology; it is a founding member of the China County-Level Medical Community Alliance and an industry-standard enterprise for the National Traditional Chinese Medicine Cardiovascular Standardized Diagnosis and Treatment Center. The “Pengyang ECG Intelligent AI Diagnostic System” won the First Prize in the 2018 National Medical Artificial Intelligence Competition, and the “18-Lead Ambulatory ECG Diagnostic System” won the First Prize in the 4th China Medical Device Innovation and Entrepreneurship Competition in 2021. In 2021, the “Expert Consensus on 18-Lead Ambulatory Electrocardiography” was published in the authoritative industry journal Chinese Journal of Cardiovascular Research.

Pengyang Medical has consistently adhered to an innovation-driven development model propelled by the dual engines of technology and market expansion. To date, the company’s products have been granted 5 national invention patents, 12 utility model patents, and 26 computer software copyrights, with plans to continue building a patent pool comprising over 100 items in the future. Currently, its products have entered more than 100 Grade A tertiary hospitals across China. The company has collaborated with Beijing Anzhen Hospital to establish a National-Level Consultation Center and partnered with provincial-level Grade A tertiary hospitals nationwide to set up regional remote ECG diagnostic centers. These initiatives have extended services downward to cover thousands of medical institutions, forming a platform-based service model characterized by multi-party collaboration, precise operations, and shared benefits. This approach has achieved a win-win outcome where the public gains access, hospitals acquire effective tools, the government obtains data, and the enterprise generates revenue.With outstanding capabilities in technological and business model innovation, Pengyang Medical has gained recognition from numerous industry experts and brand users, while also attracting significant attention from investors. Despite the severe impact of the pandemic on the market, the company has achieved profitability for consecutive years, leveraging its superior product strength and market operational capabilities. Currently, an Initial Public Offering (IPO) is on the company’s agenda. Moving forward, Pengyang Medical will continue to scale up its operations, expand its coverage within the national medical institution market, and pursue ecological collaborations with new channels such as health check-up centers, elderly care facilities, and insurance providers. Its ultimate goal is to build China’s most authoritative cardiovascular diagnostic service platform with the highest medical value.